Replimune skin cancer drug that became FDA flashpoint is rejected again - statnews.com
Source:STAT
A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.
Related Articles
Tesla Profit Forecasts Slashed Amid Musk's Spending Spree - Investor's Business Daily
Analysts are reducing Tesla earnings expectations following fourth-quarter earnings.
Why do airlines hate basic economy passengers? - The Washington Post
Major airlines are cutting frequent-flier miles for basic economy passengers, with United, American …
Asian Stocks Gain Before Fed, Oil Holds Near $103: Markets Wrap - Bloomberg.com
Stocks rose across the world as sharp swings in oil markets subsided while traders awaited …
Bank of Canada, Major Lenders Meet on Anthropic AI Cyber Risk - Bloomberg.com
The Bank of Canada and the country’s major banks and financial firms met Friday to discuss …